Neoadjuvant Treatment for Resectable NSCLC & Deep Dive on Options for PD-L1<1% mNSCLC

Bristol Myers Squibb

Program Objectives:

  • Thoracic Surgeon Jacques-Pierre Fontaine, M.D. discusses the latest clinical data and surgical considerations for neoadjuvant treatment of patients with resectable NSCLC
  • PD-L1<1% 1L mNSCLC patient case discussion and treatment considerations
  • Medical Oncologist Kent Shih, M.D. reviews the clinical evidence and additional follow-up data supporting the use of immunotherapy combinations for first-line treatment of patients with metastatic NSCLC across squamous and non-squamous histologies

© 2021 FLASCO | Premium Website Design by The HDG